GILD - Gilead Sciences, Inc. Stock Price and Quote

GILD [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	NDX, S&P 500	P/E	22.26	EPS (ttm)	3.64	Insider Own	0.08%	Shs Outstand	1.25B	Perf Week	4.91%
Market Cap	99.41B	Forward P/E	11.22	EPS next Y	7.22	Insider Trans	-4.13%	Shs Float	1.23B	Perf Month	1.36%
Income	4.59B	PEG	8.81	EPS next Q	1.57	Inst Own	83.00%	Short Float / Ratio	1.23% / 2.45	Perf Quarter	-3.98%
Sales	27.28B	P/S	3.64	EPS this Y	-26.20%	Inst Trans	0.86%	Short Interest	15.20M	Perf Half Y	30.33%
Book/sh	16.92	P/B	4.79	EPS next Y	5.62%	ROA	7.30%	Target Price	88.96	Perf Year	37.93%
Cash/sh	5.20	P/C	15.57	EPS next 5Y	2.52%	ROE	22.30%	52W Range	57.17 - 89.74	Perf YTD	-4.92%
Dividend	3.00	P/FCF	21.45	EPS past 5Y	-13.90%	ROI	13.10%	52W High	-9.04%	Beta	0.40
Dividend %	3.71%	Quick Ratio	1.20	Sales past 5Y	0.90%	Gross Margin	79.30%	52W Low	42.79%	ATR	1.66
Employees	17000	Current Ratio	1.30	Sales Q/Q	2.00%	Oper. Margin	26.90%	RSI (14)	54.51	Volatility	2.01% 2.02%
Optionable	Yes	Debt/Eq	1.19	EPS Q/Q	328.30%	Profit Margin	16.80%	Rel Volume	0.70	Prev Close	80.97
Shortable	Yes	LT Debt/Eq	1.08	Earnings	Feb 02 AMC	Payout	79.80%	Avg Volume	6.20M	Price	81.63
Recom	2.50	SMA20	2.54%	SMA50	-0.77%	SMA200	10.58%	Volume	1,229,180	Change	0.81%

Jan-03-23

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$87

Dec-13-22

Resumed

BofA Securities

Neutral

$85

Dec-09-22

Downgrade

DZ Bank

Buy → Hold

$90

Oct-31-22

Upgrade

Barclays

Underweight → Equal Weight

$60 → $76

Oct-28-22

Upgrade

Truist

Hold → Buy

$76 → $91

Oct-28-22

Upgrade

Piper Sandler

Neutral → Overweight

$79 → $96

Oct-28-22

Reiterated

Wells Fargo

Equal Weight

$74 → $75

Oct-28-22

Reiterated

RBC Capital Mkts

Outperform

$79 → $82

Oct-28-22

Reiterated

JP Morgan

Overweight

$80 → $87

Oct-28-22

Reiterated

Jefferies

Buy

$78 → $86

Show Previous Ratings

Mar-29-23 10:35AM	Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities ACCESSWIRE
08:00AM	Investors more bullish on Gilead Sciences (NASDAQ:GILD) this week as stock climbs 4.1%, despite earnings trending downwards over past year Simply Wall St.
Mar-28-23 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Mar-27-23 11:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover Morningstar Research
09:25AM	Gilead Sciences Could Retreat Further From Here TheStreet.com
08:45AM	Loading…
Mar-26-23 08:45AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover Morningstar Research
Mar-23-23 01:51PM	Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval Zacks
Mar-22-23 05:50PM	Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
02:38PM	Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study Zacks
12:00PM	Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities Business Wire
09:30AM	Groups Around the World Work to Eliminate Hepatitis C by Meeting People Where They Are ACCESSWIRE
Mar-21-23 01:19PM	Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients Benzinga
10:05AM	Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead Zacks
09:37AM	Kites Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma Business Wire
Mar-20-23 12:17PM	Gilead Exercises First License Option Under Agreement With Nurix Therapeutics Benzinga
09:00AM	Loading…
09:00AM	Nurixs stock rallies on Gileads option MarketWatch
08:30AM	Gilead Exercises Option to License Nurixs IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 GlobeNewswire
08:30AM	Gilead Exercises Option to License Nurixs IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Business Wire
Mar-16-23 05:45PM	Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
12:10PM	Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain? Zacks
07:30AM	Heres Why Gilead Sciences (GILD) Outperformed in Q4 Insider Monkey
07:00AM	Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly Simply Wall St.
Mar-15-23 05:50PM	Gilead Sciences (GILD) Stock Moves -0.15%: What You Should Know Zacks
03:38PM	Medicare identifies drug makers that will owe penalties for raising prices on 27 drugs faster than rate of inflation Yahoo Finance
12:50PM	First Drugs Facing Medicare Price Penalty Are Named The Wall Street Journal
10:25AM	Stacey Bledsoe's Resolve To Make Clinical Trials Available to Everyone ACCESSWIRE
Mar-12-23 09:00AM	Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84% Simply Wall St.
Mar-09-23 05:45PM	Gilead Sciences (GILD) Stock Moves -1.55%: What You Should Know Zacks
01:24PM	Analyst Report: Gilead Sciences, Inc. Argus Research
01:09PM	Market Update: RY, GILD, KSS, SRE Argus Research
09:25AM	Loading…
Mar-08-23 09:25AM	Gilead Sciences: Global Community Accountability Groups Pave Way Forward for Inclusive Clinical Trials ACCESSWIRE
09:00AM	Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 50% Discount? Simply Wall St.
Mar-07-23 09:37AM	2 Healthcare Stocks That Could Help Set You Up for Life Motley Fool
Mar-06-23 07:29AM	What Contributed to Gilead Sciences (GILD)s Outperformance in Q4? Insider Monkey
Mar-03-23 05:45PM	Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
Mar-02-23 10:25AM	Gilead Foundation Donating $1 Million for Relief Efforts in Türkiye and Syria ACCESSWIRE
06:00AM	How Did Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Fare Against The Industry? Simply Wall St.
Feb-28-23 09:30AM	Honoring the History and Impact of the Aids Memorial Quilt ACCESSWIRE
Feb-27-23 04:11PM	Top 10 Drug Companies in USA and Their China Reliance Insider Monkey
Feb-26-23 02:12PM	7 Cash-Rich Companies to Invest in During Economic Uncertainty InvestorPlace
09:00AM	The one-year decline in earnings for Gilead Sciences NASDAQ:GILD) isn't encouraging, but shareholders are still up 38% over that period Simply Wall St.
Feb-25-23 06:25AM	3 Stocks to Buy Right Now That Are Cash Cows Motley Fool
Feb-24-23 11:40AM	WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants MarketWatch
Feb-23-23 04:26PM	Cambridge biotech Jounce to cut staff, merge with U.K. drug developer American City Business Journals
10:30AM	Gilead Sciences: Black HIV/AIDS Awareness Day ACCESSWIRE
Feb-22-23 11:37AM	Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment Benzinga
11:21AM	Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV Business Wire
11:00AM	GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill Reuters
09:00AM	Kite Completes Acquisition of Tmunity Business Wire
Feb-21-23 05:46PM	Gilead says its COVID-19 drug can help reduce deaths, shorten hospital stays MarketWatch
05:30PM	Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients Business Wire
03:01PM	Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies Business Wire
10:13AM	The Argus High-Yield Model Portfolio Argus Research
09:25AM	Gilead Listed on the 2023 Bloomberg Gender-Equality Index ACCESSWIRE
05:22AM	Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75 Simply Wall St.
Feb-20-23 11:53AM	Gilead (GILD) Reports Positive Data From Urothelial Cancer Study Zacks
10:34AM	25 Most Profitable NASDAQ Stocks Today Insider Monkey
10:17AM	Billionaire Ken Griffins Top 10 High Dividend Stock Picks Insider Monkey
Feb-17-23 09:30AM	Mobile Clinics Expand Access to Cancer Screenings in the U.S. South ACCESSWIRE
09:00AM	Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer Business Wire
Feb-15-23 11:30AM	4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gileads Research Footprint ACCESSWIRE
Feb-14-23 08:45AM	Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 Business Wire
Feb-10-23 11:03AM	Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy Zacks
Feb-09-23 12:17PM	Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings Benzinga
12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update Zacks
08:00AM	2 Biotech Stocks That Could Make You Richer Motley Fool
07:15AM	Kites Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Business Wire
Feb-08-23 08:30AM	Gilead Sciences: 4 Questions With See Phan: Discovering New Therapies in Breast Cancer ACCESSWIRE
Feb-07-23 05:19AM	Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75 Simply Wall St.
Feb-06-23 01:27PM	Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod Zacks
05:41AM	Is Gilead Sciences a Good Stock to Buy Now? Motley Fool
Feb-03-23 04:16PM	Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology Zacks
04:07PM	Analyst Report: Gilead Sciences, Inc. Morningstar Research
04:01PM	Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years Investor's Business Daily
03:57PM	Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript Insider Monkey
12:54PM	Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting Benzinga
12:51PM	Dan O'Day delivers clear Gilead message: stability, sustainability American City Business Journals
12:46PM	15 Best Dividend Leaders to Buy According to Hedge Funds Insider Monkey
11:17AM	Gilead Posts Its Best Growth In 7 Years As Cancer Drug Sales Skyrocket Investor's Business Daily
10:50AM	UPDATE 3-Gilead's breast cancer drug gets U.S. FDA approval for third indication Reuters
10:29AM	U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer Business Wire
05:51AM	Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years? Motley Fool
04:26AM	Gilead (GILD) Reports Q4 Earnings: What Key Metrics Have to Say Zacks
Feb-02-23 09:00PM	Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript Motley Fool
07:27PM	Analyst Report: Gilead Sciences, Inc. Morningstar Research
05:35PM	Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates Zacks
05:14PM	Gilead stock jumps 5% after Q4 beat, dividend increase MarketWatch
04:05PM	Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend Business Wire
04:01PM	Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results Business Wire
04:00PM	Gilead Issues Unexpectedly Bullish Outlook After Cancer Drug Sales Rocket Investor's Business Daily
09:00AM	Gilead Sciences: Toward Health Equity for Black People Impacted by TNBC ACCESSWIRE
Feb-01-23 10:44AM	Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others Zacks
10:16AM	Top 25 Smartest Companies To Buy According To Hedge Funds Insider Monkey
09:00AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings Zacks
08:35AM	Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer Business Wire
08:32AM	Why Gilead (GILD) Might Surprise This Earnings Season Zacks
Jan-30-23 12:10PM	Why Gilead (GILD) is Poised to Beat Earnings Estimates Again Zacks
09:00AM	Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma Business Wire
Jan-27-23 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences Business Wire
Jan-26-23 05:45PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parsey Merdad	Chief Medical Officer	Mar 13	Sale	78.99	6,126	483,893	70,130	Mar 14 06:20 PM
Lofton Kevin E	Director	Mar 09	Option Exercise	52.38	8,442	442,192	8,442	Mar 10 05:23 PM
Parsey Merdad	Chief Medical Officer	Mar 01	Sale	79.96	12,984	1,038,225	70,130	Mar 02 07:01 PM
Parsey Merdad	Chief Medical Officer	Dec 30	Sale	85.33	553	47,187	45,556	Jan 03 08:05 PM
Dickinson Andrew D	Chief Financial Officer	Dec 10	Option Exercise	0.00	1,027	0	69,695	Dec 13 03:11 PM
Wilfong Diane E.	SVP, Controller & CAO	Nov 09	Option Exercise	63.91	6,416	410,047	34,749	Nov 10 04:20 PM
Wilfong Diane E.	SVP, Controller & CAO	Nov 09	Sale	83.50	6,416	535,736	28,333	Nov 10 04:20 PM
Wilfong Diane E.	SVP, Controller & CAO	Nov 01	Option Exercise	72.70	16,255	1,181,738	44,588	Nov 02 04:57 PM
Wilfong Diane E.	SVP, Controller & CAO	Nov 01	Sale	79.25	16,255	1,288,209	28,333	Nov 02 04:57 PM
Lofton Kevin E	Director	Apr 28	Option Exercise	25.62	16,322	418,251	90,525	Apr 29 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience